Steven P Sparagana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6433917/publications.pdf

Version: 2024-02-01

172457 189892 5,721 53 29 citations h-index papers

g-index 56 56 56 5506 docs citations times ranked citing authors all docs

50

#	Article	IF	Citations
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	2.1	1,185
2	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	2.1	693
3	Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2013, 381, 125-132.	13.7	687
4	Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. Journal of Medical Genetics, 2010, 47, 332-341.	3.2	447
5	Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genetics in Medicine, 2007, 9, 88-100.	2.4	353
6	RENAL LESION GROWTH IN CHILDREN WITH TUBEROUS SCLEROSIS COMPLEX. Journal of Urology, 1998, 160, 141-145.	0.4	277
7	Diagnosis of Tuberous Sclerosis Complex. Journal of Child Neurology, 2004, 19, 643-649.	1.4	239
8	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	2.1	230
9	Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncology, The, 2014, 15, 1513-1520.	10.7	152
10	Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS ONE, 2016, 11, e0158476.	2.5	146
11	Tuberous sclerosis complex. Current Opinion in Neurology, 2000, 13, 115-119.	3.6	112
12	LONG-TERM OUTCOME OF TRANSCATHETER EMBOLIZATION OF RENAL ANGIOMYOLIPOMAS DUE TO TUBEROUS SCLEROSIS COMPLEX. Journal of Urology, 2005, 174, 1764-1766.	0.4	104
13	Early Diagnosis of Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis. Journal of Child Neurology, 1998, 13, 173-177.	1.4	97
14	Change in corpus allatum function during metamorphosis of the tobacco hornwormManduca sexta: Regulation at the terminal step in juvenile hormone biosynthesis. Archives of Insect Biochemistry and Physiology, 1986, 3, 321-338.	1.5	81
15	The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrology Dialysis Transplantation, 2014, 29, 1203-1210.	0.7	79
16	Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene. Annals of Neurology, 2000, 47, 517-520.	5.3	63
17	Functional Assessment of <i>TSC < /i> 2 Variants Identified in Individuals with Tuberous Sclerosis Complex. Human Mutation, 2013, 34, 167-175.</i>	2.5	60
18	Juvenile hormone acid methyltransferase activity in imaginal discs of Manduca sexta prepupae. Archives of Insect Biochemistry and Physiology, 1985, 2, 191-202.	1.5	58

#	Article	IF	Citations
19	Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy. CNS Drugs, 2019, 33, 593-604.	5.9	57
20	Sexual Dimorphism in Juvenile Hormone Synthesis by Corpora Allata and in Juvenile Hormone Acid Methyltransferase Activity in Corpora Allata and Accessory Sex Glands of Some Lepidoptera. International Journal of Invertebrate Reproduction and Development, 1988, 13, 87-99.	0.7	45
21	Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex. Human Mutation, 2012, 33, 476-479.	2.5	45
22	Seizure Remission and Antiepileptic Drug Discontinuation in Children With Tuberous Sclerosis Complex. Archives of Neurology, 2003, 60, 1286-9.	4.5	43
23	Longâ€ŧerm cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open″abel extension trial. Epilepsia, 2022, 63, 426-439.	5.1	39
24	Juvenile hormone production, juvenile hormone esterase, and juvenile hormone acid methyltransferase in corpora allata ofManduca sexta. The Journal of Experimental Zoology, 1984, 230, 309-313.	1.4	38
25	Mutation update for the <i>SATB2</i> gene. Human Mutation, 2019, 40, 1013-1029.	2.5	38
26	The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatric Nephrology, 2018, 33, 101-109.	1.7	37
27	Epilepsy and Neurodevelopmental Comorbidities in Tuberous Sclerosis Complex: A Natural History Study. Pediatric Neurology, 2020, 106, 10-16.	2.1	37
28	Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy. Human Molecular Genetics, 2017, 26, 4937-4950.	2.9	32
29	Spinal Cord Monitoring in Patients With Spinal Deformity and Neural Axis Abnormalities. Spine, 2006, 31, E698-E706.	2.0	25
30	Brain MRI abnormalities and spectrum of neurological and clinical findings in three patients with proximal 16p11.2 microduplication. American Journal of Medical Genetics, Part A, 2014, 164, 2003-2012.	1.2	19
31	Epilepsy treatment patterns among patients with tuberous sclerosis complex. Journal of the Neurological Sciences, 2018, 391, 104-108.	0.6	19
32	Variants Within <i>TSC2</i> Exons 25 and 31 Are Very Unlikely to Cause Clinically Diagnosable Tuberous Sclerosis. Human Mutation, 2016, 37, 364-370.	2.5	16
33	<i>TSC2</i> c.1864C>T variant associated with mild cases of tuberous sclerosis complex. American Journal of Medical Genetics, Part A, 2017, 173, 771-775.	1.2	15
34	Electroencephalography in holoprosencephaly: findings in children without epilepsy. Clinical Neurophysiology, 2003, 114, 1908-1917.	1.5	13
35	Evidence for involvement of TRE-2 (USP6) oncogene, low-copy repeat and acrocentric heterochromatin in two families with chromosomal translocations. Human Genetics, 2006, 120, 227-237.	3.8	10
36	Epilepsy and Electroencephalographic Abnormalities in SATB2-Associated Syndrome. Pediatric Neurology, 2020, 112, 94-100.	2.1	10

#	Article	IF	Citations
37	Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. PLoS ONE, 2017, 12, e0186235.	2.5	10
38	Optic Nerve Tumor in Tuberous Sclerosis Complex is not Responsive to Sirolimus. Pediatric Neurology, 2010, 42, 443-446.	2,1	9
39	Genomic Analyses of Patients With Unexplained Early-Onset Scoliosis. Spine Deformity, 2014, 2, 324-332.	1.5	9
40	A Wireless System for Monitoring Transcranial Motor Evoked Potentials. Annals of Biomedical Engineering, 2011, 39, 517-523.	2.5	8
41	Abnormal Sudomotor Function in the Hypomelanotic Macules of Tuberous Sclerosis Complex. Journal of Child Neurology, 2000, 15, 529-532.	1.4	7
42	Holoprosencephaly: A Review. American Journal of Electroneurodiagnostic Technology, 2002, 42, 59-72.	0.2	7
43	Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas. Urology, 2017, 104, 110-114.	1.0	7
44	Microneurosurgery for Neonatal Brachial Plexus Palsy. Archives of Neurology, 2006, 63, 1033.	4.5	6
45	Spinal Cord Monitoring With Transcranial Motor Evoked Potentials inÂPatients With Neural Axis Abnormalities Undergoing Spinal Deformity Surgery. Spine Deformity, 2013, 1, 205-210.	1.5	4
46	A wireless system improves reliability of intraoperative monitoring recordings. , 2016, , .		4
47	Electromagnetic interference in intraoperative monitoring of motor evoked potentials and a wireless solution. Medical Engineering and Physics, 2016, 38, 87-96.	1.7	4
48	A miniature power-efficient bidirectional telemetric platform for in-vivo acquisition of electrophysiological signals. , 2011 , , .		2
49	Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2 Journal of Clinical Oncology, 2012, 30, 10619-10619.	1.6	2
50	A wireless solution for intraoperative monitoring. , 2015, , .		1
51	mTORC1 inhibition for epilepsy in TSC. Neurology, 2016, 87, 974-975.	1.1	1
52	Use of transcranial motor-evoked potentials to provide reliable intraoperative neuromonitoring for the Charcot–Marie–Tooth population undergoing spine deformity surgery. Spine Deformity, 2022, 10, 411-418.	1.5	1
53	Report of clinical results in intraoperative wireless recording. , 2016, , .		0